Frequently Asked Questions About 3696.HK

What does InSilico Medicine Cayman TopCo do?

InSilico Medicine Cayman TopCo (3696.HK) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 3696.HK's market cap?

InSilico Medicine Cayman TopCo (3696.HK) has a market capitalization of approximately $25.61 billion, as of July 21, 2026, based on the most recent share price and shares outstanding.

Does 3696.HK pay a dividend?

No — InSilico Medicine Cayman TopCo (3696.HK) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 3696.HK profitable?

InSilico Medicine Cayman TopCo (3696.HK) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

3696.HK (InSilico Medicine Cayman TopCo) is a recent IPO.

It began trading on December 30, 2025, giving it less than a year of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates — the affected sections are flagged individually so you can tell limited history from missing data.

3696.HK

InSilico Medicine Cayman TopCo

HKSE·Biotechnology · Healthcare

HK$44.24HK$0.34−0.76%

Market capHK$25.61B·Market closed·Jul 21 8:08 AM UTC

Price Chart

HK$44.24−HK$0.34 (−0.76%)today

+47.57%

Select date range

FromTo

Dec 30, 2025Dec 30, 2025 → Jul 21, 2026· 7 moJul 21, 2026

Key Metrics

3696.HK does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateMar 30

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

Income Statement Flow

PRO

See exactly how 3696.HK's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 3696.HK and 80,000+ other tickers.

About InSilico Medicine Cayman TopCo

InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The company is also involved in research and development collaboration, software solutions, business development, new drug…

CEO: Aleksandrs Zhavoronkov
Sector: Healthcare
Industry: Biotechnology
Exchange: HKSE
Employees: 317
Website: insilico.com

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 3696.HK

What does InSilico Medicine Cayman TopCo do?: InSilico Medicine Cayman TopCo (3696.HK) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 3696.HK's market cap?: InSilico Medicine Cayman TopCo (3696.HK) has a market capitalization of approximately $25.61 billion, as of July 21, 2026, based on the most recent share price and shares outstanding.
Does 3696.HK pay a dividend?: No — InSilico Medicine Cayman TopCo (3696.HK) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 3696.HK profitable?: InSilico Medicine Cayman TopCo (3696.HK) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.